FindTrial
Sign In

A real world study of CDK4/6 inhibitor in the treatment of advanced breast cancer

A real world study of CDK4/6 inhibitor in the treatment of advanced breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128833
Enrollment
Unknown
Registered
2026-07-27
Start date
2023-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic breast cancer

Interventions

Palbociclib group:None
Abemaciclib group:None
Dalpiciclib group:None

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.advanced or metastatic breast cancer patients; 2.patients treated with CDK4/6 inhibitors;

Exclusion criteria

Exclusion criteria: 1.Patients with incomplete clinical data;

Design outcomes

Primary

MeasureTime frame
Progression free survival;—

Secondary

MeasureTime frame
Overall survival;Objective response rate;Adverse events;—

Countries

China

Contacts

Public ContactDing Haiying

Zhejiang Cancer Hospital

dinghy@zjcc.org.cn+86 571 8812 2438

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026